Management of Elevated PSA in Men Aged ≥ 80 Years

Age‑Based Screening Recommendations

In men older than 70 years, any potential survival benefit from PSA‑based screening would not appear until 9–10 years after the initial test, making it unlikely to be realized for an 81‑year‑old patient. 1

The 5‑year relative survival for localized or regional prostate cancer is essentially 100 %, and the majority of cancers diagnosed at this age remain clinically silent without causing morbidity. 1
Screen‑detected prostate cancers are overdiagnosed in 23 %–42 % of cases, with the highest rates observed in elderly men. 1

Digital rectal examination and prostate biopsy should be avoided in asymptomatic men of this age group unless they develop obstructive urinary symptoms that require diagnostic evaluation. 1
The recommended management for an elderly patient with mildly elevated PSA is to discontinue PSA screening altogether, reassure the patient about the indolent nature of most prostate cancers at this age, and rely on clinical assessment (e.g., symptoms such as bone pain or urinary obstruction) rather than serial PSA measurements to detect clinically significant disease. 1

Guidelines addressing PSA monitoring in the context of testosterone replacement therapy are not relevant to this scenario because the patient is not receiving testosterone; therefore, those recommendations should not influence management decisions. [2][3]